Phase 3
Completed N=447
Nebulized Hypertonic Saline for Bronchiolitis
Source: ClinicalTrials.gov NCT00619918 ↗Enrolled (actual)
447
Serious AEs
0.0%
Results posted
Oct 2013
Primary outcomePrimary: Admission Rate — 55; 76; 141; 107 participants
Summary
This study aims to examine the effect of nebulized 3% hypertonic saline in the treatment of viral bronchiolitis. The investigators hypothesize that nebulized 3% saline will decrease rate of hospital admission, decrease clinical severity scores, and decrease length of stay.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Admission Rate |
55; 76; 141; 107 | — |
| PRIMARY Length of Stay |
2.87; 2.86 | — |
| PRIMARY Change in RDAI Score |
1.032; 0.8557 | — |
| SECONDARY Hours of Oxygen Use |
32.88; 31.39 | — |
| SECONDARY IV Fluid Use |
51.38; 59.73 | — |
| SECONDARY Number of Participants With Supplemental Medication Use |
39; 39 | — |
Eligibility Criteria
Inclusion Criteria
- clinical diagnosis of viral bronchiolitis
- between November and April
Exclusion Criteria
- prematurity < 34 weeks
- chronic lung disease
- congenital heart disease
- history of wheezing, asthma or albuterol use
- tracheostomy status
- need for intensive care of assisted ventilation
Data sourced from ClinicalTrials.gov (NCT00619918). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.